Leder, B. Z., Zapalowski, C., Hu, M., Hattersley, G., Lane, N. E., Singer, A. J., & Dore, R. K. (2019). Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial. J Bone Miner Res.

Leder, Benjamin Z., Carol Zapalowski, Ming‐Yi Hu, Gary Hattersley, Nancy E. Lane, Andrea J. Singer, et Robin K. Dore. "Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated With Abaloparatide Followed By Alendronate: Results From the Phase 3 ACTIVExtend Trial." J Bone Miner Res 2019.

Leder, Benjamin Z., et al. "Fracture and Bone Mineral Density Response By Baseline Risk in Patients Treated With Abaloparatide Followed By Alendronate: Results From the Phase 3 ACTIVExtend Trial." J Bone Miner Res 2019.